Table 1.
Baseline characteristics of Study A participants by dosage group.
| - | - |
Below Median
DED (<1.25) at month 4 (n=225) Mean DED 0.68 |
At or Above Median DED (≥1.25) at month 4 (n=252) Mean DED 2.33 | |
|---|---|---|---|---|
| Measure | Category | n (%) | n (%) | P Chisq |
| Sex | Male Female |
95 (42.2%) 130 (57.8%) |
164 (65.1%) 88 (34.9%) |
< 0.001 |
| PKD genotype – 4 levels | NMD | 22 (10.2%) | 17 (6.9%) | 0.27 |
| PKD1-NT | 56 (25.9%) | 75 (30.4%) | ||
| PKD1-T | 107 (49.5%) | 110 (44.5%) | ||
| PKD2 | 31 (14.4%) | 45 (18.2%) | ||
| Previous use of any ARB | Yes | 38 (18.4%) | 46 (19.2%) | 0.83 |
| Previous use of any ACE-Inhibitor | Yes | 96 (46.6%) | 126 (52.7%) | 0.20 |
| Treatment group | Lis + Tel Lis + Placebo |
83 (36.9%) 142 (63.1%) |
158 (62.7%) 94 (37.3%) |
< 0.001 |
| Blood pressure group | Low BP Standard BP |
79 (35.1%) 146 (64.9%) |
166 (65.9%) 86 (34.1%) |
< 0.001 |
| MRI Class ǂ | 1A + 2A | 32 (14.3%) | 20 (8.0%) | 0.09 |
| 1B + 1C | 118 (52.9%) | 142 (56.8%) | ||
| 1D + 1E | 73 (32.7%) | 88 (35.2%) | ||
| Measure (continuous) at baseline | Mean ± SD | Mean ± SD | ProbF | |
| Age (years) | 37.0 ± 8.1 | 36.8 ± 8.2 | 0.77 | |
| BMI (kg/m2) | 26.8 ± 5.1 | 28.0 ± 5.1 | 0.01 | |
| Average home systolic BP (mmHg) | 121.1 ± 7.2 | 127.6 ± 9.7 | < 0.001 | |
| Average home diastolic BP (mmHg) | 81.8 ± 7.0 | 84.1 ± 7.8 | < 0.01 | |
| CKD EPI eGFR (mL/min/1.73 m2) | 92.3 ± 17.0 | 89.4 ± 17.3 | 0.06 | |
| Urine aldosterone (µg/24 hrs) | 13.1 ± 10.2 | 11.1 ± 9.4 | 0.01* | |
| Urine sodium (mEq/24 hrs) | 177.8 ± 82.9 | 183.2 ± 79.4 | 0.48 | |
| Urine albumin (mg/24 hrs): Median (p25, p75) | 19.6 (12.2, 32.4) | 17.7 (11.8, 33.3) | 0.55* | |
| Total kidney volume (mL) | 1186.3 ± 737.1 | 1304.1 ± 741.3 | 0.02* | |
| Height-adjusted TKV (mL/m) | 682.1 ± 409.6 | 736.1 ± 409.1 | 0.05* | |
| Renal blood flow (mL/min/1.73 m2) | 576.5 ± 197.9 | 625.8 ± 210.9 | 0.03 | |
| Left ventricular mass index (g/m2) | 61.4 ± 12.2 | 67.1 ± 12.0 | < 0.001 | |
*p value from log-transformed variable.